 Healio | Combination of ibrutinib and rituximab produced high response rates in high ... Healio ATLANTA — The combination of ibrutinib and rituximab produced favorable overall response rates among high-risk patients with chronic lymphocytic leukemia, according to study results presented at the 2012 American Society of Hematology Meeting and ... |
